AKT1 and breast neoplasm: While hyper-activation of ERK1/2 inducing MAPK cascade has been reported in nearly 50% of breast tumors, aberrant activity of PI3K/Akt signaling is observed in 70% of all breast adenocarcinomas [9, 10].